Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNTY-102
- Development stage
- Discontinued
- Lead developer
- Century Therapeutics
- Modality
- Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CNTY-102 is an induced pluripotent stem cell (iPSC)-derived, chimeric antigen receptor (CAR) gamma delta iT cell therapy being developed by Century Therapeutics for the treatment of relapsed/refractory B-cell lymphoma and other B-cell malignancies. It is designed as a multi-specific CAR-T therapy to simultaneously target the B-cell antigens CD19 and CD22 (some sources indicate CD79b as the second target, but the majority specify CD22), with the aim of increasing the depth and durability of response by overcoming resistance mechanisms such as CD19 antigen loss. Its primary mechanism of action is inhibiting or depleting B-cells by targeting these surface antigens, leading to cytotoxic killing of malignant B-cells. CNTY-102 utilizes iPSC technology to generate allogeneic, off-the-shelf gamma delta T cell products. The route of administration is intravenous. Development was led by Century Therapeutics, but preclinical development in B-cell lymphoma has been discontinued as of 2023[3][7][9][12].
- Other names
- CNTY-102CNTY102CNTY 102
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CNTY-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNTY-102.